Five-year award signals FDA’s commitment to national program utilizing electronic healthcare data to monitor the safety of FDA-regulated drugs and other medical products
CHICAGO–(BUSINESS WIRE)–Oct. 10, 2019–
Veradigm™, an Allscripts (NASDAQ: MDRX) business unit dedicated to simplifying healthcare with data-driven health insights and technologies to help manage cost and improve health outcomes, announced today that its Life Sciences business unit joins the Harvard Pilgrim Healthcare Institute and other collaborating partners to continue to develop the FDA Sentinel System, the largest multisite distributed database in the world dedicated to drug safety. The award focuses on two areas: first, managing the Sentinel Operations Center, which builds upon the Institute’s 10 years of experience developing and operating the Sentinel System; and second, developing a new Sentinel Innovation Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005125/en/
According to the FDA, the Operations Center will continue to leverage organizational partnerships in the areas of epidemiology, clinical medicine, pharmacy, statistics, health informatics, data science and network operations, to support post approval safety analyses. The Innovation Center will be focused on developing innovative methods to further advance Sentinel, including exploring novel ways to extract and structure information from electronic health records (EHRs).
As a business unit of Allscripts, one of the world’s largest EHR providers, Veradigm is especially well positioned to help the Harvard Pilgrim team achieve FDA’s objective to better utilize information from EHRs in the next phase of Sentinel development. Veradigm currently offers HealthInsights, the largest deidentified EHR database available for life sciences research (~150m patients) that has been linked to integrated claims for certain research studies. In addition, Veradigm collaborates with healthcare providers to implement point-of-care research programs, engaging patients and prospectively collecting additional data using Allscripts EHR platforms.
“Veradigm is excited to collaborate with Harvard Pilgrim to continue to advance the Sentinel System,” said Tom Langan, Chief Executive Officer for Veradigm. “I believe our position as the Life Sciences-focused business unit of Allscripts enables us to approach the challenge in innovative ways, helping to increase efficiency, responsiveness and the scale of Sentinel.”
Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics, and media. Our solutions are designed to help key healthcare stakeholders to improve the quality, efficiency, and value of healthcare delivery – from biopharma to health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. That is how we are transforming health, insightfully. To learn more, visit www.veradigmhealth.com. Veradigm™ is a business unit of Allscripts.
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.